Preclinical vs Phase 1 — Immunology Deal Valuation Comparison
Market Analysis
The Preclinical to Phase 1 transition in immunology represents a significant value inflection point. Phase 1 deals carry a median total deal value of $1.3B compared to $904M at Preclinical, a 46% premium reflecting clinical de-risking. Upfront payments increase from $63M to $144M.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the deal value premium from Preclinical to Phase 1 in immunology?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating